Back to Results
First PageMeta Content
Asthma / Respiratory therapy / Chronic lower respiratory diseases / Bioethics / Pharmacology / Tiotropium bromide / Salmeterol / Placebo / Chronic obstructive pulmonary disease / Medicine / Health / Pulmonology


Once-daily tiotropium Respimat® add-on to ICS ± LABA improves control across asthma severities[removed]Tiotropium Respimat® for use in asthma is currently being reviewed by regulatory
Add to Reading List

Document Date: 2014-09-07 00:03:40

Open Document

File Size: 265,73 KB

Share Result on Facebook

City

Groningen / Pisa / Tokyo / Riss / Rhein / Cape Town / Ingelheim / Sendai / San Diego / /

Company

Gilead / Takeda / Boehringer Ingelheim / P Novartis / Genentech / MedImmune / Merck / GSK / Pharmaxis / Aerocrine / AstraZeneca / /

Country

Germany / Ecuador / Netherlands / Italy / South Africa / Chile / Thailand / Colombia / Japan / Russia / United States / Canada / /

Currency

pence / /

Facility

3University Hospital of Pisa / Ken Ohta / 4 Masakazu Ichinose / 5 Petra Moroni-Zentgraf / 6 Michael Engel / 6 Hendrik Schmidt / 7 Eric Bateman8 University of British Columbia / National Hospital / University Medical Center Groningen / University Graduate School / /

MedicalCondition

symptomatic asthma / COPD / asthma / disease / improved asthma / severe asthma / /

Organization

American Academy of Allergy / Asthma & Immunology Annual / 3University Hospital of Pisa / 4Tokyo National Hospital / University of British Columbia / Vancouver / American Thoracic Society / GINA Science Committee References / Graduate School / European Union / /

Person

Lianne Young (Hons) / Mark FitzGerald / /

Position

Executive and a member / Chair / /

Product

SPIRIVA / /

ProvinceOrState

Oregon / British Columbia / California / /

SocialTag